Skip to main content
Full access
Government News
Published Online: 1 March 2016

APA Urges Psychiatrists to Support ECT Device Reclassification

The Food and Drug Administration (FDA) is again proposing to reclassify electroconvulsive therapy (ECT) from a Class III (high risk) medical device to Class II (low risk). Opposition from anti-psychiatry groups was blamed for the FDA’s maintaining Class III status in 2011.
APA urges psychiatrists to submit their comments to the FDA in favor of the reclassification. The FDA’s draft guidance on the proposed reclassification and a link to post comments can be accessed here. Also posted at that site is a template letter that provides talking points. The FDA must receive comments by March 28.■

Information & Authors

Information

Published In

History

Published online: 1 March 2016
Published in print: February 20, 2016 – March 4, 2016

Keywords

  1. ECT Device Reclassification
  2. FDA

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share